In vivo testing revealed that immunization with thenewly designed vaccine construct bearing the GalNAc glycocluster induceda higher titer of anti-Tn-MUC1 antibodies compared to the TACAs alone.Additionally, the antibodies obtained bind a library of tumor-associatedsaccharide structures on MUC1 and MUC1-positive breast cancer cells.Conjugation of a high-affinity ligand for MGL to tumor-associatedMUC1 glycopeptide antigens has a synergistic impact on antibody production. Here, MUC1 is linked to breast carcinoma.